MedTrace Logo

To Evaluate the Impact of MRSA Nasal Screen Implementation.

NCT07748143 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2026-08-05

No results posted yet for this study

Summary

To evaluate the impact of MRSA nasal screen implementation on duration of therapy and cost associated with vancomycin use.

Conditions

  • MRSA

Interventions

OTHER

Duration of therapy

The final data will then be compared to determine if the duration of therapy and cost after implementation of the MRSA nasal screen if significantly different from before the implementation of the MRSA nasal screen.

OTHER

Direct Cost

Direct costs of vancomycin for each treatment arm (in US dollars).

OTHER

Pharmacokinectic Monitoring

Number of vancomycin levels drawn for pharmacokinetic monitoring.

OTHER

Hospital stay

Length of hospital stay in days

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Daniel Betina · Methodist Health System

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2026-06-01
Completion
2026-06-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07748143 on ClinicalTrials.gov